Acumen director awarded RSUs and stock options

Acumen Pharmaceuticals director Derrell Porter received new equity awards.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Acumen Pharmaceuticals director Derrell Porter received new equity awards. He was granted 35,500 restricted stock units, each representing one share of common stock, which will vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, subject to his continuous service.

Porter was also granted stock options for 53,250 shares of common stock at an exercise price of $2.29 per share, expiring on June 3, 2036, with the same vesting schedule. Following these grants, he directly holds 48,300 shares of common stock.

Insider Trade Summary

Grant/Award: 88,750 shares

Grant/Award 2 txns

Insider Porter Derrell

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	53,250	$0.00	$0.00
Grant/Award	Common Stock	35,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 53,250 contracts (Direct); Common Stock — 48,300 shares (Direct)

Footnotes (2)

F1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
F2. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

RSU award: 35,500 units Stock options granted: 53,250 options Option exercise price: $2.29/share +2 more

5 metrics

RSU award 35,500 units Restricted stock units granted to director Derrell Porter

Stock options granted 53,250 options Options on common stock granted as compensation

Option exercise price $2.29/share Strike price for 53,250 stock options

Option expiration June 3, 2036 Expiration date of granted stock options

Shares held after grant 48,300 shares Common stock directly held by Derrell Porter after transactions

Key Terms

restricted stock unit ("RSU"), Stock Option (right to buy), annual stockholder meeting, continuous service

4 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right..."

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of 2.2900 per share..."

annual stockholder meeting financial

"will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting..."

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Derrell Porter receive from Acumen Pharmaceuticals (ABOS)?

Derrell Porter received 35,500 restricted stock units and stock options for 53,250 shares of Acumen Pharmaceuticals common stock. Both awards were granted as compensation and vest on the same schedule tied to his continued board service and the 2027 annual stockholder meeting.

How do the new RSUs for Acumen Pharmaceuticals (ABOS) director Derrell Porter vest?

The 35,500 RSUs vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting. Vesting is conditioned on Porter’s continuous service through that date, meaning he must remain in his role until the vesting trigger.

What are the key terms of Derrell Porter’s stock options at Acumen Pharmaceuticals (ABOS)?

Porter received stock options for 53,250 shares of common stock at an exercise price of $2.29 per share. These options vest in full on the earlier of the first anniversary of grant or the 2027 annual stockholder meeting and expire on June 3, 2036.

How many Acumen Pharmaceuticals (ABOS) shares does Derrell Porter hold after these grants?

After the equity grants, Derrell Porter directly holds 48,300 shares of Acumen Pharmaceuticals common stock. This figure reflects his non-derivative common stock position as reported, separate from the 35,500 RSUs and 53,250 stock options that were newly granted.

Are Derrell Porter’s recent Acumen Pharmaceuticals (ABOS) transactions open-market purchases or sales?

The transactions are grants, not open-market trades. Porter acquired 35,500 RSUs and 53,250 stock options as compensation awards, both reported with transaction code A, indicating grants or awards rather than discretionary buying or selling in the market.

When do Derrell Porter’s Acumen Pharmaceuticals (ABOS) stock options expire?

The stock options granted to Derrell Porter expire on June 3, 2036. They cover 53,250 shares at an exercise price of $2.29 per share and must vest first under the time-based schedule linked to the 2027 annual stockholder meeting or the grant anniversary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/05/2026 - 04:30 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Porter Derrell

(Last)

(First)

(Middle)

C/O ACUMEN PHARMACEUTICALS, INC.

1210-1220 WASHINGTON STREET, SUITE 210

(Street)

NEWTON

MASSACHUSETTS

02465

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acumen Pharmaceuticals, Inc. [ ABOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/03/2026		A		35,500⁽¹⁾	A	$0	48,300	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$2.29	06/03/2026		A		53,250		⁽²⁾	06/03/2036	Common Stock	53,250	$0	53,250	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

2. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Derek Meisner, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR